Picking a PI in Multiple Myeloma: Asking & Answering the W5

Picking a PI in Multiple Myeloma: Asking & Answering the W5 is organized by Integrity Continuing Education Inc.

Expires: Dec 12, 2020

Accreditation:
Integrity Continuing Education, Inc. designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Description:
Once considered an inevitable death sentence within a matter of months, multiple myeloma (MM) can now, in many cases, be transformed into a long-term chronic illness that can often be managed for decades. Recent advances in genomics and gene sequencing have led to a better understanding of the myeloma microenvironment in the pathophysiology of MM, which has in turn yielded new therapies that target the diseases through immunomodulatory, cellular, and genetic pathways. Proteasome inhibitors (PIs), specifically, are used across the continuum of care, and have become the backbone of treatment combinations in the relapsed/refractory MM (RRMM) setting, particularly in high-risk disease. However, there is no one standard of care for this disease, due to its complex and nuanced nature.

Objectives :
• Differentiate between the PIs, outlining the efficacy and safety profiles, advantages and disadvantages, and quality of life impact of each
• Select tailored treatment combinations for a cytogenetically high-risk MM patient at first and second relapse
• Expound the rationale for PI-based treatment combinations for patients with RRMM